LONDON & BOSTON & SAN FRANCISCO & TOKYO--(BUSINESS WIRE)--Evaluate Ltd, the life science commercial intelligence firm, today announced that it has received significant investment from HgCapital’s Mercury Fund to support the Company’s strategic growth plans. Financial terms have not been disclosed.
Evaluate is the trusted source for life science commercial intelligence and analysis with exclusive consensus forecasts to 2022. It has a range of online subscription database services covering the pharmaceutical, biotech, and medtech sectors. The Company also provides project-based analytical and data services, and has an award-winning editorial team, EP Vantage.
The investment from HgCapital’s Mercury Fund will enable Evaluate to strengthen its position, further grow its customer base, and support its strategy to expand the breadth of intelligence and forecasts it provides to its customers.
Jonathan de Pass, Founder and Chairman of Evaluate, said: “Partnering with HgCapital enables us to realise our vision of becoming the leading provider of commercial intelligence on the life sciences market backed up by the best possible service to our clients. The management team and I warmly welcome the HgCapital team to Evaluate as we position our business for the next leg of growth.”
David Issott, Director of the Mercury Team, said: “Evaluate was the first company of its kind to offer such specialist intelligence services and since its inception has had a track record of consistent growth. Our investment in Evaluate represents the Mercury team’s approach to investing into technology infrastructure businesses that occupy growing niches. We have great confidence in the team and the business.”
About Evaluate Ltd
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information please visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.
